Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label study of nifedipine GITS + candesartan cilexetil fixed-dose combination in adults with moderate to severe essential hypertension
2012-004515-32Phase 3Completed
- Sponsor
- Bayer
- Start
- Dec 2012
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of nifedipine and candesartan cilexetil in essential hypertension (4 arms), sponsored by Bayer. Primary endpoint: Incidence of adverse events and adverse events of special interest. Started Dec 2012; status: completed.
02
Drugs
nifedipinecandesartan cilexetil
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2012-004515-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004515-32.